MX2020002644A - Variantes del miembro 1 de la familia 14 del grupo portador de solutos (slc14a1) y usos de estas. - Google Patents
Variantes del miembro 1 de la familia 14 del grupo portador de solutos (slc14a1) y usos de estas.Info
- Publication number
- MX2020002644A MX2020002644A MX2020002644A MX2020002644A MX2020002644A MX 2020002644 A MX2020002644 A MX 2020002644A MX 2020002644 A MX2020002644 A MX 2020002644A MX 2020002644 A MX2020002644 A MX 2020002644A MX 2020002644 A MX2020002644 A MX 2020002644A
- Authority
- MX
- Mexico
- Prior art keywords
- slc14a1
- solute carrier
- carrier family
- variants
- disclosure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762555440P | 2017-09-07 | 2017-09-07 | |
| PCT/US2018/049674 WO2019051033A1 (en) | 2017-09-07 | 2018-09-06 | VARIANTS OF MEMBER 1 OF SOLUT TRANSPORTER FAMILY 14 (SLC14A1) AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002644A true MX2020002644A (es) | 2020-10-07 |
Family
ID=63714031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002644A MX2020002644A (es) | 2017-09-07 | 2018-09-06 | Variantes del miembro 1 de la familia 14 del grupo portador de solutos (slc14a1) y usos de estas. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20190071683A1 (enExample) |
| EP (1) | EP3679060A1 (enExample) |
| JP (1) | JP2020536500A (enExample) |
| KR (1) | KR20200062224A (enExample) |
| CN (1) | CN111278851A (enExample) |
| AU (1) | AU2018330458A1 (enExample) |
| CA (1) | CA3074682A1 (enExample) |
| IL (1) | IL272981A (enExample) |
| MX (1) | MX2020002644A (enExample) |
| RU (1) | RU2020112313A (enExample) |
| SG (1) | SG11202001792UA (enExample) |
| WO (1) | WO2019051033A1 (enExample) |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5294533A (en) | 1988-07-05 | 1994-03-15 | Baylor College Of Medicine | Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria |
| US5135917A (en) | 1990-07-12 | 1992-08-04 | Nova Pharmaceutical Corporation | Interleukin receptor expression inhibiting antisense oligonucleotides |
| US5271941A (en) | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
| US5786138A (en) | 1993-01-29 | 1998-07-28 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Hyperstabilizing antisense nucleic acid binding agents |
| DE69425890D1 (de) | 1993-06-04 | 2000-10-19 | Us Health | Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide |
| US5578716A (en) | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
| US5641754A (en) | 1994-01-10 | 1997-06-24 | The Board Of Regents Of The University Of Nebraska | Antisense oligonucleotide compositions for selectively killing cancer cells |
| WO1996005298A1 (en) | 1994-08-09 | 1996-02-22 | Ciba-Geigy Ag | Antitumor antisense oligonucleotides |
| US5856103A (en) | 1994-10-07 | 1999-01-05 | Board Of Regents The University Of Texas | Method for selectively ranking sequences for antisense targeting |
| US5994320A (en) | 1995-02-06 | 1999-11-30 | Regents Of The University Of Minnesota | Antisense oligonucleotides and methods for treating central nervous system tumors |
| IT1275862B1 (it) | 1995-03-03 | 1997-10-24 | Consiglio Nazionale Ricerche | Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento |
| US6040296A (en) | 1995-06-07 | 2000-03-21 | East Carolina University | Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation |
| AU7286696A (en) | 1995-10-13 | 1997-05-07 | F. Hoffmann-La Roche Ag | Antisense oligomers |
| CN1202900A (zh) | 1995-11-21 | 1998-12-23 | Icn药品公司 | 用il－8和il－8受体的反义寡核苷酸抑制肿瘤生长 |
| WO1997029757A1 (en) | 1996-02-15 | 1997-08-21 | National Institutes Of Health | Rnase l activators and antisense oligonucleotides effective to treat rsv infections |
| US5955590A (en) | 1996-07-15 | 1999-09-21 | Worcester Foundation For Biomedical Research | Conjugates of minor groove DNA binders with antisense oligonucleotides |
| US6046004A (en) | 1997-02-27 | 2000-04-04 | Lorne Park Research, Inc. | Solution hybridization of nucleic acids with antisense probes having modified backbones |
| JPH1142091A (ja) | 1997-07-25 | 1999-02-16 | Toagosei Co Ltd | アンチセンス核酸化合物 |
| US6046319A (en) | 1997-10-22 | 2000-04-04 | University Technologies International, Inc. | Antisense oligodeoxynucleotides regulating expression of TNF-α |
| US6007995A (en) | 1998-06-26 | 1999-12-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of TNFR1 expression |
| US6013522A (en) | 1999-02-23 | 2000-01-11 | Isis Pharmaceuticals Inc. | Antisense inhibition of human Smad1 expression |
| US6025198A (en) | 1999-06-25 | 2000-02-15 | Isis Pharmaceuticals Inc. | Antisense modulation of Ship-2 expression |
| US6033910A (en) | 1999-07-19 | 2000-03-07 | Isis Pharmaceuticals Inc. | Antisense inhibition of MAP kinase kinase 6 expression |
| JP2008526249A (ja) * | 2005-01-13 | 2008-07-24 | プロジェニカ・バイオファーマ・エス・アー | ｉｎｖｉｔｒｏ遺伝子タイピングのための方法および製品 |
| US9234897B2 (en) * | 2005-03-31 | 2016-01-12 | Two Cells Co., Ltd | Method for distinguishing mesenchymal stem cell using molecular marker and use thereof |
| EP1825850A1 (en) * | 2006-02-24 | 2007-08-29 | DSMIP Assets B.V. | Use of resveratrol and derivatives thereof for promoting the wellness state in mammals |
| WO2008003826A1 (en) * | 2006-07-07 | 2008-01-10 | Oy Jurilab Ltd | Novel genes and markers in essential arterial hypertension |
| JP2009039040A (ja) * | 2007-08-09 | 2009-02-26 | Otsuka Pharmaceut Factory Inc | ヒトにおけるＳＬＣトランスポーターのｍＲＮＡの測定方法、そのためのプローブ及びキット |
| WO2012095872A1 (en) * | 2011-01-13 | 2012-07-19 | Decode Genetics Ehf | Genetic variants as markers for use in urinary bladder cancer risk assessment, diagnosis, prognosis and treatment |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| DK3363902T3 (da) | 2012-12-06 | 2020-01-02 | Sigma Aldrich Co Llc | Crispr-baseret genommodifikation og -regulering |
| WO2015039972A1 (en) * | 2013-09-17 | 2015-03-26 | Bayer Pharma Aktiengegesellschaft | Modulators of slc22a13 |
| CA3001637A1 (fr) * | 2015-10-16 | 2017-04-20 | Universite Paris 7-Denis Diderot | Procede de production de proteines erythrocytaires |
-
2018
- 2018-09-06 SG SG11202001792UA patent/SG11202001792UA/en unknown
- 2018-09-06 KR KR1020207009932A patent/KR20200062224A/ko not_active Withdrawn
- 2018-09-06 EP EP18779863.2A patent/EP3679060A1/en not_active Withdrawn
- 2018-09-06 RU RU2020112313A patent/RU2020112313A/ru unknown
- 2018-09-06 WO PCT/US2018/049674 patent/WO2019051033A1/en not_active Ceased
- 2018-09-06 US US16/123,373 patent/US20190071683A1/en not_active Abandoned
- 2018-09-06 CA CA3074682A patent/CA3074682A1/en active Pending
- 2018-09-06 MX MX2020002644A patent/MX2020002644A/es unknown
- 2018-09-06 JP JP2020513750A patent/JP2020536500A/ja active Pending
- 2018-09-06 CN CN201880068095.7A patent/CN111278851A/zh active Pending
- 2018-09-06 AU AU2018330458A patent/AU2018330458A1/en not_active Withdrawn
-
2020
- 2020-03-01 IL IL272981A patent/IL272981A/en unknown
-
2021
- 2021-04-08 US US17/225,405 patent/US20210230609A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20190071683A1 (en) | 2019-03-07 |
| CN111278851A (zh) | 2020-06-12 |
| RU2020112313A3 (enExample) | 2022-02-24 |
| WO2019051033A1 (en) | 2019-03-14 |
| US20210230609A1 (en) | 2021-07-29 |
| CA3074682A1 (en) | 2019-03-14 |
| KR20200062224A (ko) | 2020-06-03 |
| AU2018330458A1 (en) | 2020-03-19 |
| IL272981A (en) | 2020-04-30 |
| SG11202001792UA (en) | 2020-03-30 |
| JP2020536500A (ja) | 2020-12-17 |
| RU2020112313A (ru) | 2021-10-08 |
| EP3679060A1 (en) | 2020-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017015888A2 (pt) | dispositivo, adesivo de eletromiografia, e método para determinar e/ou monitorar o esforço respiratório de um indivíduo; e programa de computador | |
| White | The globalisation of mental illness | |
| WO2016069591A9 (en) | Compositions, methods and use of synthetic lethal screening | |
| MY202410A (en) | Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring | |
| ZA201801083B (en) | Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof | |
| MX2020000604A (es) | Métodos terapéuticos y de diagnóstico para el cáncer. | |
| Paul et al. | A CHIPotle in physiology and disease | |
| BR112019010943A2 (pt) | métodos para o tratamento do câncer compreendendo agentes de ligação a tigit | |
| PH12017500032B1 (en) | Improved aã protofibril binding antibodies | |
| MX2021015165A (es) | Metodos de procesamiento de un fluido que incluye una proteina terapeutica recombinante y uso de los mismos. | |
| WO2014197816A8 (en) | Stimulus responsive nanocomplexes and methods of use thereof | |
| MX2022002056A (es) | Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina. | |
| EP3688015C0 (en) | MUTATED ADENO-ASSOCIATED VIRUS CAPSID PROTEINS FOR COUPLING LIGANDS, NANOPARTICLES OR DRUGS VIA THIOETHER BONDING AND METHOD OF THEIR PRODUCTION. | |
| CO2020014681A2 (es) | Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas | |
| MX2020009532A (es) | Oligonucleotidos modificados para uso en el tratamiento de tauopatias. | |
| WO2018026969A3 (en) | Plazomicin antibodies and methods of use | |
| Ocakoğlu et al. | The shape of the external human ear: a geometric morphometric study | |
| EP4253960A3 (en) | Materials and methods for assessing cancer risk and treating cancer | |
| HUE062537T2 (hu) | Peptidek diabetes és társult betegségek kezelésére | |
| WO2017095918A3 (en) | Methods for treating cancer using rspo3 antagonists | |
| Brinster et al. | Acquired hemophilia, rheumatoid arthritis, and TNFα antagonists: Comment on the article" Acquired hemophilia possibly induced by etanercept in a patient with rheumatoid arthritis" by Banse et al., Joint Bone Spine 2015; 82: 200-2 | |
| Crawford | Commentary on" Rupestonic acid derivative YZH-106 suppresses influenza virus replication by activation of heme oxygenase-1-mediated interferon response" by Ma et al.[Free Radic. Biol. Med. 96 (2016) 347-361] | |
| EP3817280C0 (en) | ONLINE SERVICE DELIVERY SYSTEM, CI CHIP, AND APPLICATION PROGRAM | |
| TH165977A (th) | องค์ประกอบทางโภชนาการที่มีส่วนประกอบเปปไทด์และการใช้ของมัน | |
| Baeyens et al. | European Court of Justice. ECJ 2014/6 Octapharma France SAS v. Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), Ministère des Affaires Sociales et de la Santé, 13 March 2014 (C-512/12) |